S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)

Compare Stocks

Date Range: 

 Eli Lilly andAbbott LaboratoriesNovo Nordisk A/SPfizerAbbVie
SymbolNYSE:LLYNYSE:ABTNYSE:NVONYSE:PFENYSE:ABBV
Price Information
Current Price$242.31$119.34$104.65$42.09$107.45
50-Day Moving Average$246.02$123.28$100.78$45.22$111.80
52-Week Low$129.21$103.13$63.22$33.36$79.11
52-Week High$275.87$129.70$107.24$51.86$121.53
MarketRank™
Overall Score2.92.91.43.03.5
Analysis Score2.52.40.02.13.4
Community Score4.84.84.04.84.9
Dividend Score3.34.21.75.05.0
Ownership Score2.52.50.02.52.5
Earnings & Valuation Score1.30.61.30.61.9
Analyst Ratings
Consensus RecommendationBuyBuyHoldHoldBuy
Consensus Price Target$259.06$131.27N/A$44.00$126.67
% Upside from Price Target6.91% upside10.00% upsideN/A4.54% upside17.89% upside
Trade Information
Market Cap$232.38 billion$211.57 billion$246.43 billion$235.99 billion$189.88 billion
Beta0.250.660.410.740.82
Average Volume3,430,7615,373,788980,51530,012,5726,990,981
Sales & Book Value
Annual Revenue$24.54 billion$34.61 billion$19.45 billion$41.91 billion$45.80 billion
Price / Sales9.476.1112.675.634.15
Cashflow$9.05 per share$5.16 per share$3.28 per share$2.87 per share$13.83 per share
Price / Cash26.7623.1131.9514.667.77
Book Value$6.09 per share$18.62 per share$4.12 per share$11.42 per share$7.42 per share
Price / Book39.796.4125.403.6914.48
Profitability
Net Income$6.19 billion$4.50 billion$6.46 billion$9.62 billion$4.62 billion
EPS$7.93$3.65$2.76$2.22$10.56
Trailing P/E Ratio36.3333.6234.2018.0628.96
Forward P/E Ratio28.5425.6129.6512.347.73
P/E Growth1.862.452.811.582.01
Net Margins22.71%15.85%34.17%23.06%12.40%
Return on Equity (ROE)119.12%26.75%72.72%26.49%154.24%
Return on Assets (ROA)15.81%12.31%30.72%10.73%14.10%
Dividend
Annual Payout$3.40$1.80$0.77$1.56$5.20
Dividend Yield1.40%1.51%0.74%3.71%4.84%
Three-Year Dividend Growth42.31%35.85%13.65%-10.94%84.37%
Payout Ratio42.88%49.32%27.90%70.27%49.24%
Years of Consecutive Dividend Growth7 Years49 YearsN/A12 Years49 Years
Debt
Debt-to-Equity Ratio2.210.520.190.505.89
Current Ratio1.151.791.061.370.91
Quick Ratio0.891.360.801.120.79
Ownership Information
Institutional Ownership Percentage81.65%72.05%5.58%64.93%65.82%
Insider Ownership Percentage0.13%1.50%0.07%0.05%0.09%
Miscellaneous
Employees2,020109,0002,02078,5002,020
Shares Outstanding959.03 million1.77 billion2.35 billion5.61 billion1.77 billion
Next Earnings Date10/26/2021 (Confirmed)10/20/2021 (Confirmed)10/29/2021 (Estimated)11/2/2021 (Confirmed)10/29/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
20 Safe Dividend Stocks to Quit Your 9 to 5 Job20 Safe Dividend Stocks to Quit Your 9 to 5 Job
finance.yahoo.com - October 19 at 12:55 PM
FDA OKs Cyltezo As First Interchangeable Biosimilar To Humira FDA OKs Cyltezo As First Interchangeable Biosimilar To Humira
rttnews.com - October 19 at 11:17 AM
3 Leading Healthcare Stocks to Buy in 2021 and Beyond - Nasdaq3 Leading Healthcare Stocks to Buy in 2021 and Beyond - Nasdaq
nasdaq.com - October 19 at 7:54 AM
Boehringer wins interchangeable status for Humira copy, strengthening competitive threat - BioPharma DiveBoehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat - BioPharma Dive
biopharmadive.com - October 18 at 4:05 PM
Where Does AbbVie Inc (ABBV) Stock Fall in the Drug Manufacturers - General Field After It Has Fallen -2.12% This Week? - InvestorsObserverWhere Does AbbVie Inc (ABBV) Stock Fall in the Drug Manufacturers - General Field After It Has Fallen -2.12% This Week? - InvestorsObserver
investorsobserver.com - October 18 at 4:05 PM
AbbVie’s Humira to face more rivalry as FDA approves first interchangeable biosimilar - Seeking AlphaAbbVie’s Humira to face more rivalry as FDA approves first interchangeable biosimilar - Seeking Alpha
seekingalpha.com - October 18 at 9:29 AM
AbbVie suffers knock-back in Humira trade secrets dispute | IAM - IAMAbbVie suffers knock-back in Humira trade secrets dispute | IAM - IAM
iam-media.com - October 17 at 9:10 AM
AbbVie: The Humira Situation Remains ScaryAbbVie: The Humira Situation Remains Scary
seekingalpha.com - October 15 at 3:16 PM
Psoriatic Arthritis Therapeutics Drug Market Size, Forecast, and Top Firms – AbbVie, Janssen Biotech, Novartis, Amgen, CELGENE CORPORATION – Radford University Athletics - Radford University AthleticsPsoriatic Arthritis Therapeutics Drug Market Size, Forecast, and Top Firms – AbbVie, Janssen Biotech, Novartis, Amgen, CELGENE CORPORATION – Radford University Athletics - Radford University Athletics
ruhighlanders.com - October 15 at 2:57 PM
AbbVie: The Humira Situation Remains Scary - Seeking AlphaAbbVie: The Humira Situation Remains Scary - Seeking Alpha
seekingalpha.com - October 15 at 2:57 PM
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) - PRNewswireAbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) - PRNewswire
prnewswire.com - October 15 at 9:56 AM
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
finance.yahoo.com - October 15 at 9:56 AM
AbbVie Forms Flat Base Ahead Of Q3 Earnings Report - EntrepreneurAbbVie Forms Flat Base Ahead Of Q3 Earnings Report - Entrepreneur
entrepreneur.com - October 13 at 8:35 AM
AbbVie Forms Flat Base Ahead Of Q3 Earnings Report AbbVie Forms Flat Base Ahead Of Q3 Earnings Report
marketbeat.com - October 13 at 6:10 AM
5 High-Yield Stocks Trading Below GF Value5 High-Yield Stocks Trading Below GF Value
gurufocus.com - October 12 at 6:52 PM
AbbVie Inc. (ABBV) Launches Series of Initiatives to Support Breast Cancer AwarenessAbbVie Inc. (ABBV) Launches Series of Initiatives to Support Breast Cancer Awareness
markets.buffalonews.com - October 12 at 6:01 PM
AbbVie Inc.’s (NYSE: ABBV) Stock Forecast: Increase To $148.00 In A YearAbbVie Inc.’s (NYSE: ABBV) Stock Forecast: Increase To $148.00 In A Year
stocksregister.com - October 12 at 6:01 PM
AbbVie Inc.: Dissect Its Growth Sustainability And Capital Allocation Like Buffett - Seeking AlphaAbbVie Inc.: Dissect Its Growth Sustainability And Capital Allocation Like Buffett - Seeking Alpha
seekingalpha.com - October 12 at 1:01 PM
AbbVies Qulipta set to become blockbuster in the migraine market - The Pharma LetterAbbVie's Qulipta set to become blockbuster in the migraine market - The Pharma Letter
thepharmaletter.com - October 12 at 8:00 AM
Rinvoq Meets Primary Endpoints as Treatment for Active Ankylosing Spondylitis - Pharmacy TimesRinvoq Meets Primary Endpoints as Treatment for Active Ankylosing Spondylitis - Pharmacy Times
pharmacytimes.com - October 12 at 8:00 AM
Upadacitinib improves signs, symptoms of ankylosing spondylitis, nonradiographic axSpA - HealioUpadacitinib improves signs, symptoms of ankylosing spondylitis, nonradiographic axSpA - Healio
healio.com - October 12 at 1:38 AM
Should You Buy AbbVie Inc (ABBV) Stock on Monday? - InvestorsObserverShould You Buy AbbVie Inc (ABBV) Stock on Monday? - InvestorsObserver
investorsobserver.com - October 11 at 8:26 PM
Australian Association Alleges Anti-Competitive Adalimumab Antics From AbbVie - Generics BulletinAustralian Association Alleges Anti-Competitive Adalimumab Antics From AbbVie - Generics Bulletin
generics.pharmaintelligence.informa.com - October 11 at 3:26 PM
AbbVies Botox patent lawsuit is very unlikely to derail Revances rival launch: analysts - FiercePharmaAbbVie's Botox patent lawsuit is 'very unlikely to derail' Revance's rival launch: analysts - FiercePharma
fiercepharma.com - October 11 at 3:26 PM
AbbVie Stock: Price Seems Fair for Biopharmaceutical PlayAbbVie Stock: Price Seems Fair for Biopharmaceutical Play
investing.com - October 11 at 1:42 PM
Alvotech Sees AbbVies Humira Trade Secrets Case Thrown Out In US - Generics BulletinAlvotech Sees AbbVie's Humira Trade Secrets Case Thrown Out In US - Generics Bulletin
generics.pharmaintelligence.informa.com - October 11 at 9:11 AM
Can These 3 Pharma Companies Top Q2 Earnings Views? Can These 3 Pharma Companies Top Q2 Earnings Views?
marketbeat.com - July 19 at 7:53 AM
AbbVie Remains One of the Best Buys in Its Sector AbbVie Remains One of the Best Buys in Its Sector
marketbeat.com - April 29 at 11:51 AM
3 Healthy Pharmaceutical Stocks to Buy Now3 Healthy Pharmaceutical Stocks to Buy Now
marketbeat.com - April 21 at 8:27 PM
DateCompanyBrokerageAction
10/18/2021Novo Nordisk A/SSEB Equities
Upgrade
10/14/2021Abbott LaboratoriesRedburn Partners
Initiated Coverage
10/12/2021PfizerMorgan Stanley
Boost Price Target
10/11/2021Eli Lilly andBerenberg Bank
Upgrade
10/8/2021Abbott LaboratoriesCowen
Reiterated Rating
10/3/2021PfizerMizuho
Reiterated Rating
10/1/2021Abbott LaboratoriesCitigroup
Boost Price Target
9/29/2021Eli Lilly andCitigroup
Upgrade
9/24/2021Eli Lilly andJPMorgan Chase & Co.
Reiterated Rating
9/20/2021PfizerSVB Leerink
Boost Price Target
9/14/2021PfizerSVB Leerink
Reiterated Rating
9/13/2021PfizerJPMorgan Chase & Co.
Boost Price Target
9/3/2021Novo Nordisk A/SBerenberg Bank
Reiterated Rating
9/2/2021AbbVieSVB Leerink
Lower Price Target
8/31/2021Abbott LaboratoriesBTIG Research
Boost Price Target
8/30/2021Eli Lilly andCowen
Boost Price Target
8/23/2021Abbott LaboratoriesCowen
Boost Price Target
8/23/2021Novo Nordisk A/SCredit Suisse Group
Reiterated Rating
8/23/2021Novo Nordisk A/SCitigroup
Reiterated Rating
8/23/2021AbbVieCowen
Boost Price Target
8/20/2021AbbVieMorgan Stanley
Reiterated Rating
8/20/2021AbbVieSVB Leerink
Boost Price Target
8/17/2021Novo Nordisk A/SUBS Group
Reiterated Rating
8/11/2021Novo Nordisk A/SMorgan Stanley
Reiterated Rating
8/9/2021Eli Lilly andArgus
Boost Price Target
8/6/2021Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
8/5/2021Eli Lilly andDZ Bank
Upgrade
8/5/2021Novo Nordisk A/SBarclays
Reiterated Rating
8/5/2021Novo Nordisk A/SBank of America
Upgrade
8/5/2021Novo Nordisk A/SDNB Markets
Upgrade
8/5/2021AbbVieArgus
Boost Price Target
8/4/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
8/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
8/4/2021Eli Lilly andMizuho
Boost Price Target
8/3/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
8/2/2021AbbVieSVB Leerink
Boost Price Target
8/2/2021AbbVieMizuho
Boost Price Target
8/2/2021AbbVieBarclays
Boost Price Target
7/30/2021PfizerMizuho
Boost Price Target
7/29/2021PfizerThe Goldman Sachs Group
Set Price Target
7/29/2021PfizerMorgan Stanley
Boost Price Target
7/29/2021PfizerRoyal Bank of Canada
Set Price Target
7/29/2021PfizerSVB Leerink
Boost Price Target
7/27/2021Eli Lilly andTruist
Initiated Coverage
7/27/2021PfizerTruist
Initiated Coverage
7/27/2021AbbVieTruist Securities
Initiated Coverage
7/27/2021AbbVieTruist
Initiated Coverage
7/23/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
7/23/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
7/23/2021Abbott LaboratoriesRaymond James
Boost Price Target
7/20/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
7/19/2021Novo Nordisk A/SBarclays
Reiterated Rating
7/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
7/12/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
7/7/2021Eli Lilly andMizuho
Reiterated Rating
7/6/2021Eli Lilly andBarclays
Boost Price Target
7/2/2021Eli Lilly andTruist Securities
Boost Price Target
7/2/2021Eli Lilly andTruist
Boost Price Target
7/2/2021AbbVieDaiwa Capital Markets
Initiated Coverage
6/24/2021Eli Lilly andCantor Fitzgerald
Boost Price Target
6/24/2021Eli Lilly andCowen
Boost Price Target
6/17/2021PfizerRoyal Bank of Canada
Boost Price Target
6/15/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
6/15/2021PfizerBerenberg Bank
Reiterated Rating
6/14/2021Eli Lilly andThe Goldman Sachs Group
Boost Price Target
6/8/2021Eli Lilly andTruist Securities
Reiterated Rating
6/8/2021Eli Lilly andTruist Financial
Reiterated Rating
6/2/2021Abbott LaboratoriesBTIG Research
Lower Price Target
6/2/2021Abbott LaboratoriesCredit Suisse Group
Lower Price Target
6/2/2021Abbott LaboratoriesBarclays
Lower Price Target
6/2/2021Abbott LaboratoriesWells Fargo & Company
Lower Price Target
6/2/2021Abbott LaboratoriesRaymond James
Lower Price Target
6/2/2021Abbott LaboratoriesMorgan Stanley
Lower Price Target
6/2/2021Abbott LaboratoriesCitigroup
Reiterated Rating
5/24/2021Abbott LaboratoriesBarclays
Initiated Coverage
5/24/2021PfizerJPMorgan Chase & Co.
Set Price Target
5/24/2021PfizerThe Goldman Sachs Group
Set Price Target
5/13/2021PfizerThe Goldman Sachs Group
Reiterated Rating
5/12/2021PfizerMizuho
Reiterated Rating
5/10/2021PfizerMorgan Stanley
Boost Price Target
5/6/2021PfizerMizuho
Downgrade
5/5/2021PfizerSVB Leerink
Boost Price Target
5/5/2021PfizerJPMorgan Chase & Co.
Boost Price Target
5/5/2021PfizerBarclays
Boost Price Target
5/3/2021AbbVieBMO Capital Markets
Boost Price Target
5/3/2021AbbVieMizuho
Boost Price Target
4/30/2021AbbViePiper Sandler
Boost Price Target
4/28/2021Eli Lilly andMorgan Stanley
Lower Price Target
4/28/2021Eli Lilly andMizuho
Lower Price Target
4/28/2021Eli Lilly andBarclays
Lower Price Target
4/21/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
4/20/2021Abbott LaboratoriesWilliam Blair
Reiterated Rating
4/15/2021Abbott LaboratoriesAtlantic Securities
Initiated Coverage
4/7/2021PfizerRoyal Bank of Canada
Initiated Coverage
4/7/2021AbbVieRoyal Bank of Canada
Initiated Coverage
4/6/2021PfizerThe Goldman Sachs Group
Set Price Target
3/31/2021PfizerThe Goldman Sachs Group
Set Price Target
3/30/2021AbbVieSVB Leerink
Boost Price Target
3/15/2021Eli Lilly andTruist Securities
Boost Price Target
3/11/2021Abbott LaboratoriesRaymond James
Boost Price Target
2/12/2021Eli Lilly andCowen
Boost Price Target
2/11/2021Novo Nordisk A/SUBS Group
Reiterated Rating
2/4/2021Novo Nordisk A/SBarclays
Reiterated Rating
2/4/2021AbbVieSVB Leerink
Boost Price Target
2/4/2021AbbVieRoyal Bank of Canada
Boost Price Target
2/4/2021AbbVieMizuho
Boost Price Target
1/28/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
1/28/2021Abbott LaboratoriesCowen
Boost Price Target
1/28/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
1/28/2021AbbVieMorgan Stanley
Lower Price Target
1/20/2021Novo Nordisk A/SCredit Suisse Group
Downgrade
1/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Initiated Coverage
12/16/2020AbbVieSVB Leerink
Boost Price Target
12/15/2020AbbVieMizuho
Boost Price Target
11/30/2020AbbVieMorgan Stanley
Boost Price Target
11/18/2020AbbVieBMO Capital Markets
Initiated Coverage
11/12/2020Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
11/10/2020AbbVieSanford C. Bernstein
Initiated Coverage
11/6/2020Novo Nordisk A/SMorgan Stanley
Downgrade
11/3/2020Novo Nordisk A/SSociete Generale
Reiterated Rating
10/15/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
9/29/2020Novo Nordisk A/SBerenberg Bank
Initiated Coverage
8/18/2020Novo Nordisk A/SUBS Group
Reiterated Rating
8/3/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
7/6/2020Novo Nordisk A/SBank of America
Downgrade
(Data available from 10/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.